ArticlePharmaceutics2022

Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.

Guillaume Drevin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.